Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
This article was originally published in The Tan Sheet
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.